Inventor · disambiguated record
Adam P. Silverman
Also filed as: SILVERMAN ADAM · SILVERMAN ADAM P
20 granted patents·26 pending applications·67 citations·filing 2010–2024
93Inventor score
Files withDENALI THERAPEUTICS INC25UNIV LELAND STANFORD JUNIOR7CODEXIS INC5CROSSWALK THERAPEUTICS INC3COCHRAN JENNIFER R2
Top patents by PatentIndex Score
46 records- 0196US11912778B2Methods of engineering transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2022·Granted Feb 27, 2024·2 cites·17 claims
- 0296US10143187B2Transferrin receptor transgenic modelsDENALI THERAPEUTICS INC·Filed 2018·Granted Dec 4, 2018·12 cites·34 claims
- 0395US11124567B2Anti-TREM2 antibodies and methods of use thereofDENALI THERAPEUTICS INC·Filed 2021·Granted Sep 21, 2021·16 cites·31 claims
- 0493US12162948B2Methods of engineering transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2024·Granted Dec 10, 2024·1 cites·16 claims
- 0593US11970722B2Engineered acid alpha-glucosidase variantsCODEXIS INC·Filed 2020·Granted Apr 30, 2024·4 cites·39 claims
- 0693US10870837B2Fusion proteins comprising enzyme replacement therapy enzymesDENALI THERAPEUTICS INC·Filed 2019·Granted Dec 22, 2020·9 cites·47 claims
- 0789US11866742B2Fusion proteins comprising enzyme replacement therapy enzymesDENALI THERAPEUTICS INC·Filed 2020·Granted Jan 9, 2024·2 cites·35 claims
- 0888US11795232B2Engineered transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2019·Granted Oct 24, 2023·2 cites·38 claims
- 0988US2024141058A1Methods of engineering transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1087US11124562B2Anti-ApoE antibodiesUNIV WASHINGTON·Filed 2017·Granted Sep 21, 2021·3 cites·15 claims
- 1187US2024018253A1Engineered transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1285US2025297023A1Methods of engineering transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1384US8778888B2Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of useCOCHRAN JENNIFER R·Filed 2010·Granted Jul 15, 2014·4 cites·20 claims
- 1484US2025145697A1Anti-apoe antibodiesWASHINGTON UNIVERSITY ST LOUIS·Filed 2024·Application pending·0 cites
- 1582US8741839B2Polypeptides targeting vascular endothelial growth factor receptor-2 and αvβ3 integrinCOCHRAN JENNIFER R·Filed 2010·Granted Jun 3, 2014·5 cites·12 claims
- 1682US2024024432A1Engineered transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1782US2024271326A1Methods of engineering transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1880US9441026B2Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha V beta 3 integrinUNIV LELAND STANFORD JUNIOR·Filed 2014·Granted Sep 13, 2016·3 cites·4 claims
- 1979US12497605B2Engineered acid alpha-glucosidase variantsCROSSWALK THERAPEUTICS INC·Filed 2024·Granted Dec 16, 2025·0 cites·20 claims
- 2078US9234021B2Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha V beta 3 integrinUNIV LELAND STANFORD JUNIOR·Filed 2014·Granted Jan 12, 2016·2 cites·2 claims
- 2176US11926660B2Anti-ApoE antibodiesWASHINGTON UNIVERSITY ST LOUIS·Filed 2021·Granted Mar 12, 2024·0 cites·8 claims
- 2276US2023381286A1Affinity-based methods for using transferrin receptor-binding proteinsDENALI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2374US2025179460A1Human alpha-galactosidase variantsCROSSWALK THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2473US9505822B2Polypeptides targeting vascular endothelial growth factor receptor-2 and αvβ3 integrinUNIV LELAND STANFORD JUNIOR·Filed 2014·Granted Nov 29, 2016·1 cites·9 claims
- 2570US11370832B2Anti-Tau antibodies and methods of use thereofDENALI THERAPEUTICS INC·Filed 2019·Granted Jun 28, 2022·1 cites·26 claims
- 2667US2024026331A1Recombinant neprosin polypeptides and methods of expressionCODEXIS INC·Filed 2023·Application pending·0 cites
- 2767US2020369746A1Engineered transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2866US2025002887A1Engineered acid alpha-glucosidase variantsCROSSWALK THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2965US11612150B2Transferrin receptor transgenic modelsDENALI THERAPEUTICS INC·Filed 2018·Granted Mar 28, 2023·0 cites·32 claims
- 3064US2020289627A1Affinity-based methods for using transferrin receptor-binding proteinsDENALI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3163US2023279404A1Engineered oxalate decarboxylasesCODEXIS INC·Filed 2023·Application pending·0 cites
- 3262US2022177576A1Anti-trem2 antibodies and methods of use thereofDENALI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3362US2015005235A1Polypeptides Targeting Vascular Endothelial Growth Factor Receptor-2 and Alpha V Beta 3 IntegrinUNIV LELAND STANFORD JUNIOR·Filed 2014·Application pending·0 cites
- 3460US12502421B2Engineered leucine decarboxylasesSYNTIS BIO INC·Filed 2022·Granted Dec 23, 2025·0 cites·20 claims
- 3560US2021269787A1Human alpha-galactosidase variantsCODEXIS INC·Filed 2021·Application pending·0 cites
- 3659US2020277584A1Fusion proteins comprising enzyme replacement therapy enzymesDENALI THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3758US2025215077A1Monovalent anti-trem2 binding molecules and methods of use thereofDENALI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3855US2019048051A1Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha v beta 3 integrinUNIV LELAND STANFORD JUNIOR·Filed 2018·Application pending·0 cites
- 3955US2023340073A1Recombinant factor viii variantsCODEXIS INC·Filed 2023·Application pending·0 cites
- 4052US2021130485A1Transferrin receptor-binding polypeptides and uses thereofDENALI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4152US2022017634A1Engineered bispecific proteinsDENALI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4251US2016039896A1Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha v beta 3 integrinUNIV LELAND STANFORD JUNIOR·Filed 2015·Application pending·0 cites
- 4347US11773185B2Anti-BACE1 antibodies and methods of use thereofDENALI THERAPEUTICS INC·Filed 2020·Granted Oct 3, 2023·0 cites·22 claims
- 4445US2023074436A1Anti-alpha-synuclein antibodies and methods of use thereofDENALI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4543US2020317749A1Albumin variants for enhanced serum half-lifeDENALI THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4637US2016039895A1Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha v beta 3 integrinUNIV LELAND STANFORD JUNIOR·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Adam P. Silverman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →